NanoViricides, Inc. NNVC
1.34 USD -0.04 (-2.90%)
Nov 12, 2026, 1:14 PM EST
1.30 Day range 1.38
0.85 52-week range 1.93
- YTD
- +18.58%
- 1 year
- -10.67%
News
benzinga.com NanoViricides Advances NV-387 Measles Treatment Toward Clinical Trials Amid Rising Global Outbreaks / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic…
benzinga.com NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups This study is expected to pave the way for pediatric use of NV-387 in clinical trials in children possibly as young as 1 year old. Pediatric drugs for Ebola, Mpox, and Measles, as well as RSV - to…
benzinga.com NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well The Phase IIA part of the clinical trial is designed to evaluate different dosage regimens of the oral gummies for the treatment of different severity levels of the Ebola Bundibugyo virus infection…
benzinga.com NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early Enrollment NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional details on its Phase II Clinical Trial of…- benzinga.com Nanoviricides Q4 EPS $(0.10), Inline Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 23.08 percent increase over losses of $(0.13) per share from the same…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
benzinga.com NanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In Democratic Republic Of Congo Is Scheduled To Begin Next Week Clinical trial is scheduled to start at an Ebola Treatment Center in the Ituri province."NV-387 being an oral drug with broad-spectrum antiviral properties, everyone is rooting for it and hoping that…
benzinga.com NanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In DR Congo Registered In Pan African Clinical Trials Registry Database NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a…
benzinga.com NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric Disease Designation NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic…- benzinga.com World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
- benzinga.com NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of Congo Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies, has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a…
- benzinga.com NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin a Phase II…
- benzinga.com NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin a…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's pre-market session. The company's market cap stands at $27.4 million. Akanda (NASDAQ:AKAN) shares…
benzinga.com NanoVricides Applies To DRC Regulatory Agency ACOREP For Approval To Begin A Phase II Clinical Trial Of NV-387 Oral Gummies To Treat The Current Bundibugyo Ebolavirus NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team…- benzinga.com NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In Congo NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a…
- benzinga.com Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Target of $6 Noble Capital Markets analyst Robert LeBoyer initiates coverage on Nanoviricides (AMEX:NNVC) with a Outperform rating and announces Price Target of $6.
- benzinga.com NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRC NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral…
- benzinga.com FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387 NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic
- benzinga.com NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollment For Its Phase II Clinical Trial Of Monkeypox Treatment Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research Pvt. Ltd., and associates in DRC. The CRO personnel have visited the site several times, despite…
- benzinga.com NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that its proposal to perform a Phase II…
- benzinga.com NanoViricides Proposes Phase II Clinical Study Of NV-387 Oral Gummies To Congo To Treat Current Bundibugyo Ebolavirus NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed a Phase II…
- benzinga.com NanoViricides Files Prospectus For Offering $50M Mixed Shelf https://www.sec.gov/Archives/edgar/data/1379006/000110465926071007/tm2616485d1_s3.htm
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.- benzinga.com NanoViricides Prices Sale Of 1,333,334 Shares And Warrants For Gross Proceeds Of ~$2M NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine…
- benzinga.com NanoViricides' Clinical Stage, Broad-Spectrum, Antiviral Drug NV-387 Granted Orphan Drug Designation By US FDA Office Of Orphan Products Development NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic…
- benzinga.com NanoViricides Granted FDA Orphan Drug Designation Status For Treatment Of The Measles Virus https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1140226
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.- benzinga.com 66 Biggest Movers From Friday Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
- benzinga.com 31 Stocks Moving In Monday's Mid-Day Session Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to provide drone and rover…
- benzinga.com 20 Stocks Moving in Monday's Pre-Market Session Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading.
- benzinga.com 53 Biggest Movers From Yesterday Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.
- benzinga.com 46 Biggest Movers From Yesterday Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.
- benzinga.com 36 Stocks Moving In Tuesday's Mid-Day Session Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results.
- benzinga.com 62 Biggest Movers From Yesterday Gainers Intrusion Inc. (NASDAQ: INTZ) shares surged 52.1% to settle at $5.14 on Tuesday. Intrusion recently issued worse-than-expected preliminary Q2 sales results and announced the departure of its…
- benzinga.com 45 Biggest Movers From Yesterday Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.
- benzinga.com Mid-Morning Market Update: Markets Mostly Lower; Target Profit Tops Views Following the market opening Tuesday, the Dow traded up 0.04% to 31,549.29 while the NASDAQ fell 0.52% to 13,518.42. The S&P also fell, dropping 0.20% to 3,894.08.
- benzinga.com 90 Biggest Movers From Yesterday Gainers
- benzinga.com 84 Biggest Movers From Yesterday Gainers
- benzinga.com 60 Stocks Moving In Tuesday's Mid-Day Session Gainers
- benzinga.com 32 Stocks Moving in Tuesday's Pre-Market Session Gainers